Expanding treatment options for metastatic prostate cancer
about
Peptide-Based Treatment: A Promising Cancer TherapyCombining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyIn-vitro Evaluation of Cytotoxic and Apoptogenic Properties of Sophora Pachycarpa.Outpatient therapeutic nuclear oncology.Genitourinary oncology: current status and future challenges.Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancerRepurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.Androgen receptor: structure, role in prostate cancer and drug discovery.Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer.Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responsesManagement of metastatic castration-resistant prostate cancerDistinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.Use of androgen deprivation therapy in prostate cancer: indications and prevalence.Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.The effectiveness of the TAX 327 nomogram in predicting overall survival in Chinese patients with metastatic castration-resistant prostate cancer.Prostate cancer: the need for biomarkers and new therapeutic targets.Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.Characterising the castration-resistant prostate cancer population: a systematic review.Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel settingNovel options for the treatment of castration-resistant prostate cancer.Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy.Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.Targeting angiogenesis for the treatment of prostate cancer.Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.Cancer immunotherapy: a paradigm shift for prostate cancer treatment.Abiraterone for the treatment of metastatic castrate-resistant prostate cancer.The unfolding treatment landscape for men with castration-resistant prostate cancer.Prostate cancer vaccines.Overview of the latest treatments for castration-resistant prostate cancer.Current, new and novel therapy for castration-resistant prostate cancer.Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region.Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
P2860
Q26777032-70B8613D-4ADA-4E42-9929-3577E5CB0939Q26851608-E7AF673F-0E6F-4119-B41B-DB7E473C3D0FQ34146179-F0891FEB-1AC4-4A6B-BD80-2D704CE5D3C4Q34244990-5F58047F-64FA-453A-95DA-A4E7507EBC50Q34278266-D64F0B23-9F8F-491F-801D-BB0EC4C49458Q34291736-B3E7611D-7B08-4CBB-B688-8AC529D803ADQ34322294-C1535D99-32AD-4484-8F81-9916027B5C83Q34323756-F5F98FA9-50CD-4D93-8CE6-8FC1D671B09EQ35660931-9B2924BD-F710-4F19-A108-408A0261D278Q36063723-B86F259C-4133-450D-B082-2CE969538625Q36771537-5180C398-5298-47C9-8808-25DAEDB88858Q36887869-D6BD0345-0BCC-431A-9995-F0577E93007BQ36936267-2187FD09-E316-4C0E-9C34-C16D5FA9B289Q36937170-9836FC22-8A9D-4EAB-B443-4B55A51A9C0DQ37074379-93B5E3A3-6A0A-4CE0-8EC5-010CA083B5A5Q37092020-F06FA7B0-ED17-4A53-B38F-353609335819Q37437063-D8EA403C-D01F-4C0D-BFC9-152533484F1AQ37476043-9A39893A-5C52-4A19-8403-43E9A31BC23EQ37665657-1786511B-0212-4F49-997C-D5797ED8D6E6Q37945316-6EF0F861-0DCB-4504-AD77-077B2DF1060DQ37952048-0CA110E5-379B-45EE-AA1F-FD2454AEF100Q37958741-075CB42A-344D-472C-86B1-615058B434FAQ37963173-5B3B127B-AD75-4743-8054-56B089E85423Q37983730-6AB60CB3-56D0-4A8E-AFEA-1956D6AEF946Q37984189-C27AD095-C99A-456F-98E2-D1F91777D1BFQ37993137-5F426CC5-B129-4628-B833-7585EFB4FBA7Q38004275-B1D9599D-DBF1-479E-84D5-60BF49448064Q38013964-A72B0834-53BA-4EF9-9FCE-86D0F4100278Q38020132-B25F87C0-B5FE-486E-B0F1-285A2D2ACCDAQ38056914-2D51BD3B-88A7-4988-BE1E-2305DEA4FE1CQ38089935-EF3DA0C5-74B8-42DD-8960-33E40AF6C1DDQ38116754-9B8F63F0-0791-4D2A-AFF4-F4CE3CBF1D2EQ38123202-01398502-72FE-4A2B-AD74-7CBDDD3EA841Q38183819-C75CCF6A-4FAF-4034-A29F-25B65C57717BQ38375252-1D146889-ECCC-46B1-BFCA-16A69A40D5F6Q38785291-89F35E5B-AEB4-44C4-944B-13C9E05F1328Q38833356-26D5CDF0-C9F4-43DB-979A-90B6045171DAQ39063102-9D97D92D-F27E-4A33-A1DE-6744C63CFA70Q39329100-BD8FD483-6CE0-4569-A1F1-60CD9FECA1EFQ40002313-2E629B8E-61F6-4A8C-B463-6110AFD90580
P2860
Expanding treatment options for metastatic prostate cancer
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Expanding treatment options for metastatic prostate cancer
@en
Expanding treatment options for metastatic prostate cancer
@nl
type
label
Expanding treatment options for metastatic prostate cancer
@en
Expanding treatment options for metastatic prostate cancer
@nl
prefLabel
Expanding treatment options for metastatic prostate cancer
@en
Expanding treatment options for metastatic prostate cancer
@nl
P2860
P356
P1476
Expanding treatment options for metastatic prostate cancer
@en
P2093
Mario A Eisenberger
P2860
P304
P356
10.1056/NEJME1102758
P407
P577
2011-05-01T00:00:00Z